Tislelizumab-induced cytokine release syndrome: the first case report and review of the literature

作者：H. Yin, Yanwen Diao, Zheng Zhen, Qian Dong, Jingdong Zhang · 发表于：Immunotherapy · 年份：2024 · DOI：10.1080/1750743x.2024.2422814 · 被引用次数：5 · 研究领域：Cancer Immunotherapy and Biomarkers、CAR-T cell therapy research、Neuroblastoma Research and Treatments

Cytokine release syndrome (CRS) is an uncommon but deadly side effect of immune checkpoint inhibitors (ICIs). ICIs are presently an increasingly important therapy option for malignant tumors, but there are limited treatments available for CRS. We present a case of a 72-year-old man who received one cycle of ICI coupled with cisplatin and albumin-binding paclitaxel therapy for a locally advanced right lung adenocarcinoma. Following an abrupt onset of dyspnea, the patient underwent a quick physical examination, blood tests and was diagnosed with CRS. After prompt initiation of glucocorticoid pulse treatment, the symptoms relieved. The case illustrates the management of severe CRS following ICI therapy while highlighting the uncommon and potentially fatal immune-related side effects.